Robbins LLP Notifies Investors About Semler Scientific Class Action Lawsuit Claims for Securities Holders
On August 29, 2025, Robbins LLP, a firm known for its dedication to shareholder rights litigation, announced the filing of a class action lawsuit against Semler Scientific, Inc. (NASDAQ: SMLR). This legal action is aimed at individuals and entities that acquired Semler's securities during the period from March 10, 2021, to April 15, 2025. Semler Scientific is a company that specializes in technological products and services designed to aid in the evaluation and treatment of chronic diseases.
The allegations stem from claims that Semler Scientific failed to disclose crucial information regarding a significant investigation by the United States Department of Justice (DOJ) into potential violations of the False Claims Act. According to the filed complaint, during the period in question, the company did not inform investors that it was under scrutiny for alleged misconduct regarding the marketing of medical tests using photoplethysmography technology, which were improperly advertised as reimbursable by Medicare.
Investors were first made aware of this investigation on February 28, 2025, when Semler Scientific disclosed that it received an initial civil investigative demand (CID) from the DOJ in July 2017. This CID was part of an inquiry to determine whether the company had violated the False Claims Act. The seriousness of the situation escalated further when it was revealed that Semler had received multiple subsequent CIDs from the DOJ after that initial notification. On February 11, 2025, Semler attempted to engage in settlement discussions with the DOJ, but these discussions did not lead to a resolution, causing significant concern among stakeholders.
As a result of these revelations and the growing uncertainty surrounding possible legal outcomes, Semler Scientific's stock saw a dramatic drop. On March 3, 2025, after the announcement of the DOJ investigation, the shares plummeted by $4.03, translating to a 9.38% decrease, closing at $38.89.
On April 15, 2025, Semler further reported to the SEC via a Form 8-K filing, indicating that it had reached a tentative agreement with the DOJ to settle the claims for $29.75 million, excluding any attorney fees. This news did not mitigate investor concerns; instead, it added to the uncertainty with the potential for additional payments being necessary and the looming risk of a DOJ lawsuit still present. Following this announcement, Semler’s stock again declined, losing $3.40 to close at $31.00 on April 16, 2025, a 9.88% decrease.
This class action lawsuit signifies an important legal battle for both the investors affected and Semler Scientific, with implications for the company’s governance and accountability. Investors who believe they are eligible to participate in the class action are encouraged to contact Robbins LLP. Those interested in serving as lead plaintiffs—individuals representing the group in legal proceedings—should also reach out to the firm. It's important to note, participation is not mandatory to be eligible for recovery as an absent class member.
All legal representation will be charged on a contingency fee basis, meaning shareholders do not have to pay any fees or expenses unless there is a recovery. Robbins LLP, with its long-standing history in helping shareholders recover losses and ensure corporate accountability, aims to provide support and clarity during this tumultuous time.
To stay informed about the status of the class action or other corporate wrongdoing notifications, shareholders are encouraged to sign up for Stock Watch, which provides timely updates and alerts. It is critical for impacted investors to take action promptly to safeguard their rights as shareholders in this developing situation.
The allegations stem from claims that Semler Scientific failed to disclose crucial information regarding a significant investigation by the United States Department of Justice (DOJ) into potential violations of the False Claims Act. According to the filed complaint, during the period in question, the company did not inform investors that it was under scrutiny for alleged misconduct regarding the marketing of medical tests using photoplethysmography technology, which were improperly advertised as reimbursable by Medicare.
Investors were first made aware of this investigation on February 28, 2025, when Semler Scientific disclosed that it received an initial civil investigative demand (CID) from the DOJ in July 2017. This CID was part of an inquiry to determine whether the company had violated the False Claims Act. The seriousness of the situation escalated further when it was revealed that Semler had received multiple subsequent CIDs from the DOJ after that initial notification. On February 11, 2025, Semler attempted to engage in settlement discussions with the DOJ, but these discussions did not lead to a resolution, causing significant concern among stakeholders.
As a result of these revelations and the growing uncertainty surrounding possible legal outcomes, Semler Scientific's stock saw a dramatic drop. On March 3, 2025, after the announcement of the DOJ investigation, the shares plummeted by $4.03, translating to a 9.38% decrease, closing at $38.89.
On April 15, 2025, Semler further reported to the SEC via a Form 8-K filing, indicating that it had reached a tentative agreement with the DOJ to settle the claims for $29.75 million, excluding any attorney fees. This news did not mitigate investor concerns; instead, it added to the uncertainty with the potential for additional payments being necessary and the looming risk of a DOJ lawsuit still present. Following this announcement, Semler’s stock again declined, losing $3.40 to close at $31.00 on April 16, 2025, a 9.88% decrease.
This class action lawsuit signifies an important legal battle for both the investors affected and Semler Scientific, with implications for the company’s governance and accountability. Investors who believe they are eligible to participate in the class action are encouraged to contact Robbins LLP. Those interested in serving as lead plaintiffs—individuals representing the group in legal proceedings—should also reach out to the firm. It's important to note, participation is not mandatory to be eligible for recovery as an absent class member.
All legal representation will be charged on a contingency fee basis, meaning shareholders do not have to pay any fees or expenses unless there is a recovery. Robbins LLP, with its long-standing history in helping shareholders recover losses and ensure corporate accountability, aims to provide support and clarity during this tumultuous time.
To stay informed about the status of the class action or other corporate wrongdoing notifications, shareholders are encouraged to sign up for Stock Watch, which provides timely updates and alerts. It is critical for impacted investors to take action promptly to safeguard their rights as shareholders in this developing situation.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.